Research location
Preston
Lancashire, United Kingdom
Advertisement
Research activity in Preston
Lancashire, United KingdomCureCurrent currently publishes aggregate city-level research activity for this location: 32 trials and 32 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Preston
32 linked trials · page 1 of 1The Mouth Matters in Mental Health Trial -2NCT07470437 · 2026-05-01 · 1 site observation
RECRUITING
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)NCT06937229 · 2025-12-02 · 1 site observation
RECRUITING
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's DiseaseNCT07011745 · 2025-07-16 · 1 site observation
RECRUITING
Chronic Radiation Induced Bowel Toxicity StudyNCT06640959 · 2024-11-19 · 1 site observation
RECRUITING
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceNCT06492616 · 2024-09-27 · 1 site observation
RECRUITING
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)NCT06353386 · 2024-05-20 · 1 site observation
RECRUITING
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPDNCT06981078 · 2025-07-02 · 1 site observation
ACTIVE_NOT_RECRUITING
Effects of a Brown Seaweed Tart Cherry Blend in Mild-moderate HypertensionNCT06559982 · 2025-05-01 · 1 site observation
UNKNOWN
A Study to Evaluate Efficacy and Safety of Intravenous Sabirnetug in Participants With Early Alzheimer's Disease (ALTITUDE-AD)NCT06335173 · 2024-02-29 · 1 site observation
ACTIVE_NOT_RECRUITING
Effects of Peppermint Oil in Mild-moderate Hypertension.NCT05561543 · 2024-01-01 · 1 site observation
COMPLETED
Is Laryngeal Ultrasound Useful in the Assessment for ILO? A Protocol for a Two-stage Exploratory Pilot StudyNCT05686941 · 2022-08-24 · 1 site observation
UNKNOWN
Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCNCT04821622 · 2021-05-12 · 1 site observation
ACTIVE_NOT_RECRUITING
Substudy 03B: A Study of Immune and Targeted Combination Therapies in Participants With Second Line Plus (2L+) Renal Cell Carcinoma (MK-3475-03B/KEYMAKER-U03)NCT04626518 · 2020-12-17 · 1 site observation
COMPLETED
Substudy 03A: A Study of Immune and Targeted Combination Therapies in Participants With First Line (1L) Renal Cell Carcinoma (MK-3475-03A)NCT04626479 · 2020-12-16 · 1 site observation
COMPLETED
A Study to Evaluate the Efficacy and Safety of SAGE-217 in Participants With Severe Postpartum Depression (PPD)NCT04442503 · 2020-06-08 · 1 site observation
COMPLETED
DEcision-making Capacity: Intervention Development & Evaluation in Schizophrenia-spectrum DisorderNCT04309435 · 2020-02-22 · 1 site observation
UNKNOWN
Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)NCT03924869 · 2019-06-25 · 1 site observation
TERMINATED
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)NCT03898180 · 2019-05-06 · 1 site observation
COMPLETED
A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid TumorsNCT03845166 · 2019-03-20 · 1 site observation
ACTIVE_NOT_RECRUITING
Piloting MOL Intervention for Neuroleptic Decision MakingNCT03537040 · 2018-06-27 · 1 site observation
COMPLETED
Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast CancerNCT03155997 · 2017-07-12 · 1 site observation
ACTIVE_NOT_RECRUITING
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's DiseaseNCT02956486 · 2016-10-20 · 1 site observation
TERMINATED
Clozapine-induced Hypersalivation - Feasibility TrialNCT02613494 · 2016-01-25 · 1 site observation
COMPLETED
European Observational Study of Enzalutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)NCT02495974 · 2015-09-08 · 1 site observation
COMPLETED
An Open-Label, Multicenter Clinical Trial With Nivolumab (BMS-936558) Monotherapy in Subjects With Advanced or Metastatic Squamous Cell (Sq) Non-Small Cell Lung Cancer (NSCLC) Who Have Received at Least One Prior Systemic Regimen for the Treatment of Stage IIIb/IV SqNSCLCNCT02409368 · 2015-04-29 · 1 site observation
COMPLETED
Efficacy and Safety Study of Darolutamide (ODM-201) in Men With High-risk Non-metastatic Castration-resistant Prostate CancerNCT02200614 · 2014-09-12 · 1 site observation
COMPLETED
A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)NCT02034916 · 2013-12-13 · 1 site observation
TERMINATED
Metformin in Chronic Obstructive Pulmonary DiseaseNCT01247870 · 2011-01-01 · 1 site observation
COMPLETED
A Study of Chemotherapy and Ramucirumab Versus Chemotherapy Alone in Second Line Non-Small Cell Lung Cancer (NSCLC) Participants Who Received Prior First Line Platinum-based ChemotherapyNCT01168973 · 2010-12-01 · 1 site observation
COMPLETED
A Study of Thymidylate Synthase Expression in Patients With Non-Small Cell Lung CancerNCT00887549 · 2009-04-01 · 1 site observation
COMPLETED
Sunitinib Plus Prednisone In Patients With Metastatic Castration-Resistant Prostate Cancer After Failure Of Docetaxel ChemotherapyNCT00676650 · 2008-07-01 · 1 site observation
TERMINATED
Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug EfficacyNCT00268476 · 2005-07-08 · 1 site observation
ACTIVE_NOT_RECRUITING
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.